

From genomics to the clinic: Optimising ctDNA testing pathways and outcomes

Friday 12 June 2026 | 08:00–08:45
Harrogate Convention Centre, King's Road,
Harrogate, North Yorkshire, HG1 5LA

Please join us for this Menarini Stemline-sponsored symposium, where we will provide an overview of the evolving role of ctDNA testing across tumour types, along with practical insights into how testing may be incorporated into clinical pathways and support routine clinical decision-making

Prof. Ellen Copson (Chair)

Consultant Medical Oncologist,
University Hospital Southampton
NHS Foundation Trust

Dr Crispin Hiley

Consultant Clinical Oncologist and
Associate Professor with tenure
in Radiation Oncology, University
College London Hospitals NHS
Foundation Trust

Michał Śładkowski

Advanced Oncology Pharmacist,
BOPA Vice Chair Elect and E&T
Co-Chair, York and Scarborough
Teaching Hospitals NHS
Foundation Trust

Objectives

- To contextualise the evolving role of ctDNA testing across tumour types
- To support the effective implementation of ctDNA testing pathways for metastatic breast cancer within UK clinical practice
- To demonstrate how ctDNA testing can inform clinical decision-making and optimise patient outcomes

Agenda

08:00–08:05	Welcome and introduction	Prof. Ellen Copson
08:05–08:15	18 months on: Impact, insights and pathway integration for ctDNA testing – the lung perspective	Dr Crispin Hiley
08:15–08:25	ctDNA testing in breast cancer: Optimising outcomes for patients	Prof. Ellen Copson
08:25–08:35	ctDNA pathway implementation: Case study	Michał Śładkowski
08:35–08:45	Panel discussion and Q&A	All faculty

ctDNA, circulating tumour DNA.

© Menarini Stemline UK Limited. All rights reserved.

The content has been reviewed by Menarini Stemline for compliance with local regulations for the pharmaceutical industry. This material is intended for UK healthcare professionals only.

MAT-GB-ELA-00728 | May 2026